Literature DB >> 10813152

Secondary measles vaccine failures identified by measurement of IgG avidity: high occurrence among teenagers vaccinated at a young age.

M Paunio1, K Hedman, I Davidkin, M Valle, O P Heinonen, P Leinikki, A Salmi, H Peltola.   

Abstract

Failure to seroconvert (primary vaccine failure) is believed to be the principal reason (approx. > 95%) why some vaccinees remain susceptible to measles and is often attributed to the persistence of maternal antibodies in children vaccinated at a young age. Avidity testing is able to separate primary from secondary vaccine failures (waning and/or incomplete immunity), but has not been utilized in measles epidemiology. Low-avidity (LA) and high-avidity (HA) virus-specific IgG antibodies indicate primary and secondary failure, respectively. Measles vaccine failures (n = 142; mean age 10.1 years, range 2-22 years) from an outbreak in 1988-9 in Finland were tested for measles-virus IgG avidity using a protein denaturating EIA. Severity of measles was recorded in 89 failures and 169 non-vaccinees (mean age 16.2 years, range 2-22 years). The patients with HA antibodies (n = 28) tended to have clinically mild measles and rapid IgG response. Among failures vaccinated at < 12, 12-15 and > 15 months of age with single doses of Schwarz-strain vaccine in the 1970s, 50 (95% CI 1-99), 36 (CI 16-56) and 25% (CI 8-42) had HA antibodies, respectively. When a single measles, mumps and rubella (MMR) vaccine had been given after 1982 at 15 months of age, only 7% (CI 0-14) showed HA antibodies. Omitting re-vaccinees and those vaccinated at < 15 months, Schwarz-strain recipients had 3.6 (CI 1.1-11.5) higher occurrence of HA responses compared to MMR recipients. Apart from one municipality, where even re-vaccinees had high risk of primary infection, 89% (CI 69 to approximately 100) of the infected re-vaccinees had an HA response. Secondary measles-vaccine failures are more common than was more previously thought, particularly among individuals vaccinated in early life, long ago, and among re-vaccinees. Waning immunity even among individuals vaccinated after 15 months of age, without the boosting effect of natural infections should be considered a relevant possibility in future planning of vaccination against measles.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10813152      PMCID: PMC2810910          DOI: 10.1017/s0950268899003222

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  21 in total

1.  Immunity to measles in the Croatian population.

Authors:  Berislav Borcić; Renata Mazuran; Bernard Kaić
Journal:  Eur J Epidemiol       Date:  2003       Impact factor: 8.082

2.  Use of an immunoglobulin G avidity test to discriminate between primary and secondary dengue virus infections.

Authors:  Vanda Akico Ueda Fick de Souza; Silvana Fernandes; Evaldo Stanislau Araújo; Adriana Fumie Tateno; Olímpia M N P F Oliveira; Renato Reis Oliveira; Cláudio Sérgio Pannuti
Journal:  J Clin Microbiol       Date:  2004-04       Impact factor: 5.948

3.  Interpreting serological surveys using mixture models: the seroepidemiology of measles, mumps and rubella in England and Wales at the beginning of the 21st century.

Authors:  A J Vyse; N J Gay; L M Hesketh; R Pebody; P Morgan-Capner; E Miller
Journal:  Epidemiol Infect       Date:  2006-05-02       Impact factor: 2.451

4.  Measles virus-specific antibody levels in individuals in Argentina who received a one-dose vaccine.

Authors:  Marcelo H Argüelles; Mariana L Orellana; Alejandro A Castello; Guillermo A Villegas; Matilde Masini; Alejandra L Belizan; Silvia González Ayala; Osmar D Vera; Graciela Glikmann
Journal:  J Clin Microbiol       Date:  2006-08       Impact factor: 5.948

5.  Characterization of immune responses induced by intramuscular vaccination with DNA vaccines encoding measles virus hemagglutinin and/or fusion proteins.

Authors:  Man Ki Song; Christofer J Vindurampulle; Alejandra V E Capozzo; Jeffrey Ulmer; John M Polo; Marcela F Pasetti; Eileen M Barry; Myron M Levine
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

Review 6.  Measles, the need for a paradigm shift.

Authors:  Emilie Javelle; Philippe Colson; Philippe Parola; Didier Raoult
Journal:  Eur J Epidemiol       Date:  2019-10-17       Impact factor: 8.082

7.  Measles virus IgG avidity assay for use in classification of measles vaccine failure in measles elimination settings.

Authors:  Sara Mercader; Philip Garcia; William J Bellini
Journal:  Clin Vaccine Immunol       Date:  2012-09-12

8.  An Agent-Based Model of School Closing in Under-Vacccinated Communities During Measles Outbreaks.

Authors:  Wayne M Getz; Colin Carlson; Eric Dougherty; Travis C Porco Francis; Richard Salter
Journal:  Agent Dir Simul Symp       Date:  2016-04

9.  Real-time reverse transcription-PCR assay for detection of mumps virus RNA in clinical specimens.

Authors:  Jennifer D Boddicker; Paul A Rota; Trisha Kreman; Andrea Wangeman; Louis Lowe; Kimberly B Hummel; Robert Thompson; William J Bellini; Michael Pentella; Lucy E Desjardin
Journal:  J Clin Microbiol       Date:  2007-07-25       Impact factor: 5.948

10.  Identification of primary and secondary measles vaccine failures by measurement of immunoglobulin G avidity in measles cases during the 1997 São Paulo epidemic.

Authors:  Cláudio S Pannuti; Ricardo José Morello; José Cássio de Moraes; Suely Pires Curti; Ana Maria S Afonso; Maria Cláudia Corrêa Camargo; Vanda A U F de Souza
Journal:  Clin Diagn Lab Immunol       Date:  2004-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.